睾酮替代治疗可降低多数肝硬化患者的发病率和死亡率
该研究采用目标试验模拟设计,基于2008至2020年全国代表性Medicare数据,评估合并性腺功能减退的男性肝硬化患者接受睾酮替代治疗对死亡、失代偿事件和骨折风险的影响。结果发现睾酮使用与较低死亡率(sHR 0.92,95%CI 0.85-0.99)、较低新发失代偿事件风险(sHR 0.92,95%CI 0.86-0.99)相关,尤其腹水需穿刺(sHR 0.82,95%CI 0.76-0.89)和静脉曲张出血(sHR 0.67,95%CI 0.54-0.85),且未增加肝细胞癌风险(sHR 1.09,95%CI 0.91-1.3)。
要点
- 在接受睾酮治疗的患者中,治疗时间占患者日的28.6%,而未治疗者仅占0.5%(P < .0001)。
- 睾酮使用与较低死亡率(sHR 0.92,95%CI 0.85-0.99)和较低新发失代偿事件风险(sHR 0.92,95%CI 0.86-0.99)相关。
- 睾酮对腹水需穿刺(sHR 0.82,95%CI 0.76-0.89)和静脉曲张出血(sHR 0.67,95%CI 0.54-0.85)效果更明显,对肝性脑病需住院(sHR 0.92,95%CI 0.84-1.01)和骨折(sHR 0.99,95%CI 0.91-1.08)效果较小,未增加肝细胞癌风险(sHR 1.09,95%CI 0.91-1.3)。
核心结论
- 在针对全国代表性老年肝硬化合并性腺功能减退患者队列的目标试验模拟中,睾酮使用改善了临床结局。
研究设计与样本
- 采用目标试验模拟设计,评估在诊断肝硬化同时诊断性腺功能减退的男性中睾酮替代治疗的影响(新使用者设计)。
- 使用2008至2020年全国代表性Medicare数据,检查接受与未接受睾酮治疗患者的死亡、失代偿事件和骨折风险。
- 采用逆概率治疗加权平衡治疗组与未治疗组,并以意向性治疗设计评估结局。
主要发现
- 共282例(7.4%)睾丸功能减退合并肝硬化患者在诊断后接受了睾酮替代治疗。
- 接受睾酮治疗的患者治疗时间占患者日的28.6%,而未开始治疗者若治疗将占0.5%患者日(P < .0001)。
- 睾酮使用与较低死亡率相关(sHR 0.92;95%CI 0.85-0.99)。
- 睾酮使用与新发失代偿事件风险较低相关(sHR 0.92;95%CI 0.86-0.99),尤其腹水需穿刺(sHR 0.82;95%CI 0.76-0.89)和静脉曲张出血(sHR 0.67;95%CI 0.54-0.85)。
- 对肝性脑病需住院(sHR 0.92;95%CI 0.84-1.01)和骨折(sHR 0.99;95%CI 0.91-1.08)影响较小,且未增加肝细胞癌风险(sHR 1.09;95%CI 0.91-1.3)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 基线亚组间存在显著的治疗效应异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Many men with cirrhosis have low testosterone levels. This is associated with sarcopenia, anemia, and poor quality of life. Data are lacking, however, regarding the clinical impact of testosterone replacement. METHODS: We conducted an emulated clinical trial evaluating the impact of testosterone replacement among men who were diagnosed with hypogonadism at the same time as their diagnosis of cirrhosis (new user design). We used nationally representative Medicare data (2008-2020) to examine the risk of death, decompensation events, and fractures in patients who did or did not receive testosterone. We balanced treated and untreated with inverse probability of treatment weighting and evaluated outcomes using an intention-to-treat design. RESULTS: A total of 282 patients (7.4%) with testicular hypofunction and cirrhosis received testosterone replacement after diagnosis. Patients started on testosterone spent 28.6% of patient-days on therapy, and patients not started would spend 0.5% of patient-days on therapy (P < .0001). Testosterone use was associated with lower mortality (subdistribution hazard ratio [sHR], 0.92; 95% confidence interval [CI], 0.85-0.99). Testosterone also led to a lower risk of new decompensation events (sHR, 0.92; 95% CI, 0.86-0.99) and especially for ascites requiring paracentesis (sHR, 0.82; 95% CI, 0.76-0.89) and variceal hemorrhage (sHR, 0.67; 95% CI, 0.54-0.85) with less effect on hepatic encephalopathy requiring hospitalization (sHR, 0.92; 95% CI, 0.84-1.01) and fractures (sHR, 0.99; 95% CI, 0.91-1.08) and without increased risk of hepatocellular carcinoma (sHR, 1.09; 95% CI, 0.91-1.3). There was substantial heterogeneity of treatment effect across baseline subgroups. CONCLUSIONS: In our target trial emulation of a nationally representative cohort of older patients with cirrhosis and hypogonadism, testosterone use improved clinical outcomes.
引用
- Tapper EB, Chen X, Parikh ND, et al. Testosterone Replacement Reduces Morbidity and Mortality for Most Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2025. PMID: 40097035. doi:10.1016/j.cgh.2025.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。